RETRACTED: Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background and purpose: Nutrient overload leads to obesity and insulin resistance. Pioglitazone, a selective peroxisome proliferator‐activated receptor (PPAR)γ agonist, is currently used to manage insulin resistance, but the specific molecular mechanisms activated by PPARγ are not yet fully understood. Recent studies suggest the involvement of suppressor of cytokine signalling (SOCS)‐3 in the pathogenesis of insulin resistance. This study aimed to investigate the hepatic signalling pathway activated by PPARγ activation in a non‐genetic insulin‐resistant animal model. Experimental approach: Male Wistar rats were maintained on a high‐cholesterol fructose (HCF) diet for 15 weeks. Pioglitazone (3 mg·kg−1) was administered orally for the last 4 weeks of this diet. At the end of the treatment, serum was collected for biochemical analysis. Levels of PPARγ, SOCS‐3, pro‐inflammatory markers, insulin receptor substrate‐2 and Akt/glycogen synthase kinase‐3β phosphorylation were assesed in rat liver. Key results: Rats fed the HCF diet exhibited hyperlipidemia, hyperinsulinemia, impaired glucose tolerance and insulin resistance. Pioglitazone administration evoked a significant improvement in lipid metabolism and insulin responsiveness. This was accompanied by reduced hepatic expression of SOCS‐3, interleukin‐6, tumour necrosis factor‐α and markers of neutrophil infiltration. Diet‐induced PPARγ expression was unaffected by the pioglitazone treatment. Conclusion and implications: Chronic pioglitazone administration reduced hepatic inflammatory responses in rats fed a HCF diet. These effects were associated with changes in hepatic expression of SOCS‐3, which may be a crucial link between the reduced local inflammation and the improved insulin signalling. This article is commented on by Chatterjee, pp. 1889–1891 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476‐5381.2010.00739.x
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821 · cited 2×
“Changes in mRNA levels of liver-specific PPARg target genes after chronic treatment with pioglitazone To verify whether the beneficial effects of pioglitazone were correlated with a specific hepatic mechanism of PPARgdependent transcriptional modulation, we tested the effects of pioglitazone administration to HFC rats…”
Background(2006) · The Lancet · doi:10.1016/s0140-6736(06)69420-8 · Cited by 1,706 · cited 1×
“The most clinically used PPARg agonists, rosiglitazone and pioglitazone, which belong to the thiazolidinedione (TZD) class of anti-diabetic drugs, are able to manage obesity-linked insulin resistance and type 2 diabetes (Miyazaki et al., 2002; Gerstein et al., 2006).”
BackgroundInsulin sensitivity: Modulation by nutrients and inflammation
Schenk, S., Saberi, M., & Olefsky, J. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34260 · Cited by 1,191 · cited 1×
“Many lines of evidence have convincingly shown that chronic inflammation is an important pathogenic factor in the development of insulin resistance in key metabolic tissues, including the liver (Schenk et al., 2008).”
BackgroundSOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2
Rui, L., Yuan, M., Frantz, D., Shoelson, S., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200444200 · Cited by 904 · cited 1×
“SOCS-3 can modulate insulin signalling by direct association with the insulin receptor and promotion of IRS-2 degradation (Rui et al., 2002; Farrell, 2005).”
BackgroundInterleukin-6 induces cellular insulin resistance in hepatocytes.
Senn, J. J., Klover, P. J., Nowak, I. A., & Mooney, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3391 · Cited by 883 · cited 1×
“In vitro studies have clearly shown that incubation of both primary mouse hepatocytes and human hepatocarcinoma cell lines with IL-6 or TNF-a cause a near complete inhibition of insulin-induced Akt activation and the subsequent glycogen synthesis (Cheung et al., 2000; Senn et al., 2002).”
BackgroundMiyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Gross, L. S., Li, L., Ford, E. S., & Liu, S. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.5.774 · Cited by 681
Senn, J. J., Klover, P. J., Nowak, I. A., Zimmers, T. A., Koniaris, L. G., Furlanetto, R. W., & Mooney, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210689200 · Cited by 620 · cited 1×
“Senn et al. (2003) demonstrated that acute exposure to IL-6 rapidly induced an overexpression of SOCS-3 in both a hepatic cell line and in the liver of mice and this effect was associated with inhibition of hepatic insulin receptor autophosphorylation.”
Background
Cited by
Li, J.-M., Yu, R., Zhang, L.-P., Wen, S.-Y., Wang, S.-J., Zhang, X.-Y., Xu, Q., & Kong, L.-D. (2019) · Microbiome · doi:10.1186/s40168-019-0713-7 · Cited by 300
Shin, J. Y., Xun, P., Nakamura, Y., & He, K. (2013) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.051318 · Cited by 289
Mastrocola, R., Ferrocino, I., Liberto, E., Chiazza, F., Cento, A. S., Collotta, D., Querio, G., Nigro, D., Bitonto, V., Cutrin, J. C., et al. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.02.003 · Cited by 68
Self-citationGuru, B., Tamrakar, A. K., Manjula, S. N., & Prashantha Kumar, B. R. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175322 · Cited by 18
Metadata
- Authors
- Collino, M., Aragno, M., Castiglia, S., Miglio, G., Tomasinelli, C., Boccuzzi, G., Thiemermann, C., & Fantozzi, R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2010-03-08
- Volume
- 160
- Issue
- 8
- Pages
- 1892-1902
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1505664810
- Cited by
- 106
- References
- 11
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RETRACTED: Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. https://app.cochat.ai/papers/10.1111/j.1476-5381.2010.00671.x
- The paper
- Collino, M., Aragno, M., Castiglia, S., Miglio, G., Tomasinelli, C., Boccuzzi, G., Thiemermann, C., & Fantozzi, R. (2010). RETRACTED: Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2010.00671.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.